News & Events

Another successful regulatory milestone achieved

Leading on from the receipt of our Investigational Medicinal Products (IMP-MA) manufacturing licence from the UK Government regulator, the MHRA, in early 2012, Symbiosis hosted its first full MHRA cGMP inspection in December 2012.Not surprisingly, we are delighted to share with you that the inspection was successfully concluded to the satisfaction of the MHRA.

This is another significant achievement for Symbiosis and is a positive reflection on the commitment of our team here at Symbiosis to delivering operational compliance of the highest standard. As we like to say: “Right first time, every time”.

Given our focus on continuous improvement, the feedback we receive from both regulator and client audits alike are integrated into the on-going revision of our quality strategy for 2013. We work to ensure that we not only meet, but actively strive to exceed our regulatory requirements wherever we can. This means we continue to actively develop our World Class quality system. That is in the best of our clients, and therefore an absolute priority for us.

Symbiosis Pharmaceutical Services specialise in the cGMP manufacture of liquid, lyophilized, cytotoxic, conventional and biological pharmaceuticals phase I and phase II clinical trials.

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.